Beaton Management Co. Inc. bought a new position in Pfizer Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 52,712 shares of the biopharmaceutical company’s stock, valued at approximately $1,771,000. Pfizer accounts for about 1.8% of Beaton Management Co. Inc.’s investment portfolio, making the stock its 17th largest holding.

Other hedge funds have also added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. bought a new position in shares of Pfizer during the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware bought a new position in shares of Pfizer during the 2nd quarter worth $103,000. D. Scott Neal Inc. grew its position in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares in the last quarter. Herndon Capital Management LLC bought a new position in shares of Pfizer during the 2nd quarter worth $120,000. Finally, Franklin Parlapiano Turner & Welch LLC bought a new position in shares of Pfizer during the 1st quarter worth $121,000. Institutional investors and hedge funds own 69.89% of the company’s stock.

In other Pfizer news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

A number of equities analysts have recently issued reports on the company. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Friday, December 8th. UBS set a $40.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, December 6th. Deutsche Bank set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, December 6th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price objective on the stock in a research report on Thursday, November 23rd. Finally, Jefferies Group set a $39.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $38.77.

Shares of Pfizer Inc. (NYSE PFE) traded up $0.06 during midday trading on Thursday, reaching $36.64. The company’s stock had a trading volume of 15,787,200 shares, compared to its average volume of 19,909,365. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market capitalization of $218,102.86, a P/E ratio of 14.64, a PEG ratio of 2.58 and a beta of 1.01. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $36.82.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the company earned $0.61 earnings per share. analysts expect that Pfizer Inc. will post 2.59 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.49%. The ex-dividend date was Thursday, November 9th. Pfizer’s dividend payout ratio is presently 79.01%.

COPYRIGHT VIOLATION WARNING: “Beaton Management Co. Inc. Buys Shares of 52,712 Pfizer Inc. (PFE)” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/12/14/beaton-management-co-inc-buys-shares-of-52712-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.